Shopping Cart 0
Cart Subtotal
AED 0

GLOBAL ALZHEIMERS DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 10093

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 14680

Details

MARKET OUTLOOK

The Alzheimer's therapeutics and diagnostics market is expected to progress at a CAGR of 7.78% during the years 2019-2027.

The market is driven by the rise in the number of Alzheimer's cases and the growing demand for personalized drugs and affordable diagnostics tests. However, the stringent regulations for the development of drugs and clinical trials are hindering the growth of the Alzheimer's disease therapeutics and diagnostics market globally. The high cost of therapies used for the treatment of Alzheimer's disease also contributes to the same. A key challenge in the growth of the global Alzheimer's disease treatment and diagnostics market is the shortage of skilled medical practitioners across the developing countries. Also, the lack of awareness regarding new therapies that are used for the treatment of the Alzheimer's disease acts as a significant growth challenge for the global Alzheimer's disease treatment and diagnostics market over the forecast period.

The segmentation of the market is on the basis of therapeutics and diagnostics. The diagnostics tests segment is bifurcated into positron emission tomography, lumbar puncture test, magnetic resonance imaging, electroencephalography, computed tomography and other diagnostics.

 

REGIONAL OUTLOOK

Europe, Asia Pacific and North America and rest of the world are the regional segments of the global Alzheimer's therapeutic and diagnostic market. Presently, it is the Asia Pacific region that is holding the reign globally. With the government investment in the R&D for drugs and diagnostic test, which is further supported by the increasing population and the large proportion of people aged above 65 years in the regions, the demand for personalized drugs is expected to witness a boom for the Alzheimer's therapeutic and diagnostic market in this region.

The Alzheimer's therapeutics & diagnostics market in Asia-Pacific is the fastest growing market globally. The primary driver of the Alzheimer's disease therapeutics & diagnostics market in China is the burgeoning rise in the population of the country, which is thereby increasing the aging population. This aging population is vulnerable to diseases like dementia, thus causing a rise in its prevalence across the country, mainly in the semi-urban and rural provinces. According to the Ministry of Health, China is one of the leading countries in terms of the number of individuals affected by dementia, which accounts for around 20% of the dementia cases globally.

 

COMPETITIVE OUTLOOK

Some of the major players that are engaged in the market include Baxter International, Inc., Piramal Enterprises, Ltd., Sun Pharma, Biogen, Inc., F. Hoffmann-La Roche AG., Siemens Medical Solutions, AbbVie, Inc., GE Healthcare, Pfizer, Inc., Merck and Co., Amarantus Bioscience Holdings, Inc., Cognoptix, Inc. and DiaGenic ASA.

DiaGenic ASA is a life sciences company engaged in the development and delivery of patient-friendly tests to diagnose of devastating diseases at early stages. The company is currently focused on the development of IVD biomarker products and is also active in identifying gene expression signatures in blood in the field of Alzheimer's disease. MCItect and New ADtect are some of the products that are a part of the company's product portfolio. New ADtect is used for detecting mild to moderate AD.

READ MORE

Table Of Content

Scope

TABLE OF CONTENTS

1. GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. THE UNITED STATES AND EUROPE REGULATORY AGENCY

2.12. ALZHEIMER'S DISEASE ETIOLOGY

2.13. PIPELINE OUTLOOK

2.14. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.15. MARKET DRIVERS

2.15.1. GROWTH OF ALZHEIMER'S DISEASE

2.15.2. INCREASING GERIATRIC POPULATION

2.15.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.16. MARKET RESTRAINTS

2.16.1. STRINGENT GOVERNMENT REGULATIONS

2.16.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.17. MARKET OPPORTUNITIES

2.17.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.17.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.18. MARKET CHALLENGES

2.18.1. LESS AWARENESS CONCERNING NEW THERAPIES FOR ALZHEIMER'S DISEASE

2.18.2. VERY FEW SKILLED PROFESSIONALS INVOLVED IN THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. NORTH AMERICA

4.1.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.1.2. COUNTRY ANALYSIS

4.1.2.1. THE UNITED STATES

4.1.2.2. CANADA

4.2. EUROPE

4.2.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2.2. COUNTRY ANALYSIS

4.2.2.1. THE UNITED KINGDOM

4.2.2.2. FRANCE

4.2.2.3. GERMANY

4.2.2.4. SPAIN

4.2.2.5. ITALY

4.2.2.6. RUSSIA

4.2.2.7. REST OF EUROPE

4.3. ASIA-PACIFIC

4.3.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.3.2. COUNTRY ANALYSIS

4.3.2.1. CHINA

4.3.2.2. INDIA

4.3.2.3. JAPAN

4.3.2.4. AUSTRALIA & NEW ZEALAND

4.3.2.5. SOUTH KOREA

4.3.2.6. ASEAN COUNTRIES

4.3.2.7. REST OF ASIA-PACIFIC

4.4. LATIN AMERICA

4.4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.4.2. COUNTRY ANALYSIS

4.4.2.1. BRAZIL

4.4.2.2. MEXICO

4.4.2.3. REST OF LATIN AMERICA

4.5. MIDDLE EAST & AFRICA

4.5.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.5.2. COUNTRY ANALYSIS

4.5.2.1. SAUDI ARABIA

4.5.2.2. TURKEY

4.5.2.3. THE UNITED ARAB EMIRATES

4.5.2.4. SOUTH AFRICA

4.5.2.5. REST OF MIDDLE EAST & AFRICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER INTERNATIONAL, INC.

5.5. BIOGEN, INC.

5.6. COGNOPTIX, INC.

5.7. DIAGENIC ASA

5.8. F. HOFFMANN-LA ROCHE AG

5.9. GE HEALTHCARE

5.10. MERCK AND CO.

5.11. PFIZER, INC.

5.12. PIRAMAL ENTERPRISES, LTD.

5.13. SIEMENS MEDICAL SOLUTIONS

5.14. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 6 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 10 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 11 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 14 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 15 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

FIGURE LIST

FIGURE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 INVESTMENTS IN ALZHEIMER'S DISEASE TREATMENT

FIGURE 3 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 4 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)

FIGURE 5 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 6 COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS 2017 (USD BILLION)

FIGURE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 8 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 9 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 10 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 11 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 12 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 13 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 14 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 15 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2019-2027 (USD MILLION)

FIGURE 16 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 17 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 19 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 20 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 21 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 22 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 23 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 24 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 25 THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 26 FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 27 GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 28 SPAIN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 29 ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 30 RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 31 REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 32 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 33 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 34 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 35 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 36 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 37 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 38 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 39 BRAZIL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 40 MEXICO ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 41 REST OF LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 42 SAUDI ARABIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 43 TURKEY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 44 THE UNITED ARAB EMIRATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 45 SOUTH AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 46 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 INVESTMENTS IN ALZHEIMER'S DISEASE TREATMENT

FIGURE 3 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 4 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)

FIGURE 5 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 6 COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS 2017 (USD BILLION)

FIGURE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 8 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 9 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 10 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 11 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 12 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 13 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 14 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 15 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2019-2027 (USD MILLION)

FIGURE 16 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 17 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 19 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 20 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 21 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 22 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 23 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 24 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 25 THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 26 FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 27 GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 28 SPAIN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 29 ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 30 RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 31 REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 32 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 33 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 34 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 35 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 36 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 37 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 38 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 39 BRAZIL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 40 MEXICO ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 41 REST OF LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 42 SAUDI ARABIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 43 TURKEY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 44 THE UNITED ARAB EMIRATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 45 SOUTH AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 46 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 6 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 10 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 11 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 14 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 15 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. ABBVIE, INC.

2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

3. AXON NEUROSCIENCE SE

4. BAXTER INTERNATIONAL, INC.

5. BIOGEN, INC.

6. COGNOPTIX, INC.

7. DIAGENIC ASA

8. F. HOFFMANN-LA ROCHE AG

9. GE HEALTHCARE

10. MERCK AND CO.

11. PFIZER, INC.

12. PIRAMAL ENTERPRISES, LTD.

13. SIEMENS MEDICAL SOLUTIONS

14. SUN PHARMA

Company Profile

Company Profile Title

MARKET OUTLOOK

The Alzheimer's therapeutics and diagnostics market is expected to progress at a CAGR of 7.78% during the years 2019-2027.

The market is driven by the rise in the number of Alzheimer's cases and the growing demand for personalized drugs and affordable diagnostics tests. However, the stringent regulations for the development of drugs and clinical trials are hindering the growth of the Alzheimer's disease therapeutics and diagnostics market globally. The high cost of therapies used for the treatment of Alzheimer's disease also contributes to the same. A key challenge in the growth of the global Alzheimer's disease treatment and diagnostics market is the shortage of skilled medical practitioners across the developing countries. Also, the lack of awareness regarding new therapies that are used for the treatment of the Alzheimer's disease acts as a significant growth challenge for the global Alzheimer's disease treatment and diagnostics market over the forecast period.

The segmentation of the market is on the basis of therapeutics and diagnostics. The diagnostics tests segment is bifurcated into positron emission tomography, lumbar puncture test, magnetic resonance imaging, electroencephalography, computed tomography and other diagnostics.

 

REGIONAL OUTLOOK

Europe, Asia Pacific and North America and rest of the world are the regional segments of the global Alzheimer's therapeutic and diagnostic market. Presently, it is the Asia Pacific region that is holding the reign globally. With the government investment in the R&D for drugs and diagnostic test, which is further supported by the increasing population and the large proportion of people aged above 65 years in the regions, the demand for personalized drugs is expected to witness a boom for the Alzheimer's therapeutic and diagnostic market in this region.

The Alzheimer's therapeutics & diagnostics market in Asia-Pacific is the fastest growing market globally. The primary driver of the Alzheimer's disease therapeutics & diagnostics market in China is the burgeoning rise in the population of the country, which is thereby increasing the aging population. This aging population is vulnerable to diseases like dementia, thus causing a rise in its prevalence across the country, mainly in the semi-urban and rural provinces. According to the Ministry of Health, China is one of the leading countries in terms of the number of individuals affected by dementia, which accounts for around 20% of the dementia cases globally.

 

COMPETITIVE OUTLOOK

Some of the major players that are engaged in the market include Baxter International, Inc., Piramal Enterprises, Ltd., Sun Pharma, Biogen, Inc., F. Hoffmann-La Roche AG., Siemens Medical Solutions, AbbVie, Inc., GE Healthcare, Pfizer, Inc., Merck and Co., Amarantus Bioscience Holdings, Inc., Cognoptix, Inc. and DiaGenic ASA.

DiaGenic ASA is a life sciences company engaged in the development and delivery of patient-friendly tests to diagnose of devastating diseases at early stages. The company is currently focused on the development of IVD biomarker products and is also active in identifying gene expression signatures in blood in the field of Alzheimer's disease. MCItect and New ADtect are some of the products that are a part of the company's product portfolio. New ADtect is used for detecting mild to moderate AD.

READ MORE

Scope

TABLE OF CONTENTS

1. GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. THREATS OF SUBSTITUTE PRODUCT

2.2.3. BARGAINING POWER OF BUYER

2.2.4. BARGAINING POWER OF SUPPLIER

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. ETYMOLOGY

2.5. PARENT MARKET OUTLOOK

2.6. STRATEGIC BUYING CRITERIA OUTLOOK

2.7. INVESTMENTS OUTLOOK

2.8. KEY FINDINGS

2.9. INDUSTRY STRUCTURE

2.9.1. RESEARCH & DEVELOPMENT

2.9.2. MANUFACTURING

2.9.3. RAW MATERIALS

2.9.4. END-USER

2.9.5. WHOLESALERS

2.10. REGULATORY FRAMEWORK

2.11. THE UNITED STATES AND EUROPE REGULATORY AGENCY

2.12. ALZHEIMER'S DISEASE ETIOLOGY

2.13. PIPELINE OUTLOOK

2.14. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE

2.15. MARKET DRIVERS

2.15.1. GROWTH OF ALZHEIMER'S DISEASE

2.15.2. INCREASING GERIATRIC POPULATION

2.15.3. SUBSTANTIAL INVESTMENTS BY GOVERNMENT IN RESEARCH

2.16. MARKET RESTRAINTS

2.16.1. STRINGENT GOVERNMENT REGULATIONS

2.16.2. HIGH TREATMENT COSTS OF ALZHEIMER'S DISEASE

2.17. MARKET OPPORTUNITIES

2.17.1. IN-VITRO DIAGNOSTIC TECHNIQUES ARE A BOON TO THE MARKET

2.17.2. INCREASING R&D INVESTMENT IN PERSONALIZED MEDICINES

2.18. MARKET CHALLENGES

2.18.1. LESS AWARENESS CONCERNING NEW THERAPIES FOR ALZHEIMER'S DISEASE

2.18.2. VERY FEW SKILLED PROFESSIONALS INVOLVED IN THE TREATMENT OF ALZHEIMER'S DISEASE

3. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET OUTLOOK-BY THERAPEUTICS AND DIAGNOSTICS

3.1. THERAPEUTICS

3.1.1. THERAPEUTICS BY DRUGS

3.1.1.1. MARKETED DRUGS

3.1.1.2. PIPELINE DRUGS

3.1.2. THERAPEUTICS BY DISEASE STAGE

3.1.2.1. LATE STAGE: SEVERE AD

3.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD

3.1.2.3. PRODROMAL STAGE

3.1.3. THERAPEUTICS BY GENERIC AND BRANDED

3.1.3.1. BRANDED

3.1.3.2. GENERIC

3.2. DIAGNOSTICS

3.2.1. LUMBAR PUNCTURE TEST

3.2.2. POSITRON EMISSION TOMOGRAPHY

3.2.3. ELECTROENCEPHALOGRAPHY

3.2.4. MAGNETIC RESONANCE IMAGING

3.2.5. COMPUTED TOMOGRAPHY

3.2.6. OTHER DIAGNOSTICS

4. ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET-REGIONAL OUTLOOK

4.1. NORTH AMERICA

4.1.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.1.2. COUNTRY ANALYSIS

4.1.2.1. THE UNITED STATES

4.1.2.2. CANADA

4.2. EUROPE

4.2.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.2.2. COUNTRY ANALYSIS

4.2.2.1. THE UNITED KINGDOM

4.2.2.2. FRANCE

4.2.2.3. GERMANY

4.2.2.4. SPAIN

4.2.2.5. ITALY

4.2.2.6. RUSSIA

4.2.2.7. REST OF EUROPE

4.3. ASIA-PACIFIC

4.3.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.3.2. COUNTRY ANALYSIS

4.3.2.1. CHINA

4.3.2.2. INDIA

4.3.2.3. JAPAN

4.3.2.4. AUSTRALIA & NEW ZEALAND

4.3.2.5. SOUTH KOREA

4.3.2.6. ASEAN COUNTRIES

4.3.2.7. REST OF ASIA-PACIFIC

4.4. LATIN AMERICA

4.4.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.4.2. COUNTRY ANALYSIS

4.4.2.1. BRAZIL

4.4.2.2. MEXICO

4.4.2.3. REST OF LATIN AMERICA

4.5. MIDDLE EAST & AFRICA

4.5.1. MARKET BY THERAPEUTICS AND DIAGNOSTICS

4.5.2. COUNTRY ANALYSIS

4.5.2.1. SAUDI ARABIA

4.5.2.2. TURKEY

4.5.2.3. THE UNITED ARAB EMIRATES

4.5.2.4. SOUTH AFRICA

4.5.2.5. REST OF MIDDLE EAST & AFRICA

5. COMPETITIVE LANDSCAPE

5.1. ABBVIE, INC.

5.2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

5.3. AXON NEUROSCIENCE SE

5.4. BAXTER INTERNATIONAL, INC.

5.5. BIOGEN, INC.

5.6. COGNOPTIX, INC.

5.7. DIAGENIC ASA

5.8. F. HOFFMANN-LA ROCHE AG

5.9. GE HEALTHCARE

5.10. MERCK AND CO.

5.11. PFIZER, INC.

5.12. PIRAMAL ENTERPRISES, LTD.

5.13. SIEMENS MEDICAL SOLUTIONS

5.14. SUN PHARMA

6. METHODOLOGY AND SCOPE

6.1. RESEARCH SCOPE

6.2. SOURCES OF DATA

6.3. RESEARCH METHODOLOGY

 

 

 

 

TABLE LIST

TABLE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 6 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 10 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 11 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 14 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 15 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

 

 

FIGURE LIST

FIGURE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 INVESTMENTS IN ALZHEIMER'S DISEASE TREATMENT

FIGURE 3 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 4 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)

FIGURE 5 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 6 COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS 2017 (USD BILLION)

FIGURE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 8 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 9 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 10 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 11 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 12 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 13 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 14 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 15 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2019-2027 (USD MILLION)

FIGURE 16 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 17 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 19 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 20 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 21 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 22 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 23 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 24 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 25 THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 26 FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 27 GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 28 SPAIN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 29 ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 30 RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 31 REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 32 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 33 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 34 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 35 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 36 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 37 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 38 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 39 BRAZIL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 40 MEXICO ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 41 REST OF LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 42 SAUDI ARABIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 43 TURKEY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 44 THE UNITED ARAB EMIRATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 45 SOUTH AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 46 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027


List Of Figure

FIGURE LIST

FIGURE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

FIGURE 2 INVESTMENTS IN ALZHEIMER'S DISEASE TREATMENT

FIGURE 3 ALZHEIMER'S DRUGS IN THE PIPELINE BY TREATMENT FOCUS (NUMBER OF DRUGS)

FIGURE 4 GLOBAL CLINICAL TRIALS ON ALZHEIMER'S DRUG BY MECHANISM OF ACTION (%)

FIGURE 5 PEOPLE SUFFERING FROM ALZHEIMER'S DEMENTIA IN THE UNITED STATES OF DIFFERENT AGES 2017 (%)

FIGURE 6 COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS 2017 (USD BILLION)

FIGURE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS 2019-2027 (USD MILLION)

FIGURE 8 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN MARKETED DRUGS 2019-2027 (USD MILLION)

FIGURE 9 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PIPELINE DRUGS 2019-2027 (USD MILLION)

FIGURE 10 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN LATE STAGE: SEVERE AD 2019-2027 (USD MILLION)

FIGURE 11 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN EARLY/MIDDLE STAGE: MILD TO MODERATE AD 2019-2027 (USD MILLION)

FIGURE 12 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN PRODROMAL STAGE 2019-2027 (USD MILLION)

FIGURE 13 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN BRANDED 2019-2027 (USD MILLION)

FIGURE 14 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS MARKET IN GENERIC 2019-2027 (USD MILLION)

FIGURE 15 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DIAGNOSTICS2019-2027 (USD MILLION)

FIGURE 16 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN LUMBAR PUNCTURE TEST 2019-2027 (USD MILLION)

FIGURE 17 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN POSITRON EMISSION TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 18 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN ELECTROENCEPHALOGRAPHY 2019-2027 (USD MILLION)

FIGURE 19 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN MAGNETIC RESONANCE IMAGING 2019-2027 (USD MILLION)

FIGURE 20 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN COMPUTED TOMOGRAPHY 2019-2027 (USD MILLION)

FIGURE 21 GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS MARKET IN OTHER DIAGNOSTICS 2019-2027 (USD MILLION)

FIGURE 22 THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 23 CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 24 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 25 THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 26 FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 27 GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 28 SPAIN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 29 ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 30 RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 31 REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 32 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 33 CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 34 INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 35 JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 36 AUSTRALIA AND NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 37 SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 38 REST OF ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 39 BRAZIL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 40 MEXICO ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 41 REST OF LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 42 SAUDI ARABIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 43 TURKEY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 44 THE UNITED ARAB EMIRATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 45 SOUTH AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027

FIGURE 46 REST OF MIDDLE EAST AND AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027


List Of Table

TABLE LIST

TABLE 1 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY GEOGRAPHY, 2019-2027 (USD MILLION)

TABLE 2 DIFFERENT BIOMARKERS RELATED TO THE ALZHEIMER'S DISEASE

TABLE 3 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2019-2027 (USD MILLION)

TABLE 4 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 5 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN DISEASE STAGE, BY DRUGS, 2019-2027 (USD MILLION)

TABLE 6 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET IN THERAPEUTICS, BY GENERIC AND BRANDED, 2019-2027 (USD MILLION)

TABLE 7 GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY TYPES, 2019-2027 (USD MILLION)

TABLE 8 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 9 NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 10 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 11 EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 12 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET BY THERAPEUTICS AND DIAGNOSTICS 2019-2027 (USD MILLION)

TABLE 13 ASIA-PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 14 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 15 LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, 2019-2027 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. ABBVIE, INC.

2. AMARANTUS BIOSCIENCE HOLDINGS, INC.

3. AXON NEUROSCIENCE SE

4. BAXTER INTERNATIONAL, INC.

5. BIOGEN, INC.

6. COGNOPTIX, INC.

7. DIAGENIC ASA

8. F. HOFFMANN-LA ROCHE AG

9. GE HEALTHCARE

10. MERCK AND CO.

11. PFIZER, INC.

12. PIRAMAL ENTERPRISES, LTD.

13. SIEMENS MEDICAL SOLUTIONS

14. SUN PHARMA